Aims/hypothesis We explored the effects of β-aminoisobutyric acid (BAIBA) on hyperlipidaemic-condition-induced insulin resistance and inflammation as mediated through a signalling pathway involving AMP-activated protein kinase (AMPK) and peroxisome proliferator-activated receptor δ (PPARδ). Methods Mouse skeletal muscle C2C12 cells and C57BL/6J mice were treated with palmitate or a high-fat diet (HFD) and BAIBA. Inflammation and the expression of genes associated with insulin signalling were determined by western blot and quantitative real-time PCR. Selected genes from candidate pathways were evaluated by small interfering (si)RNA knockdown and specific inhibitors. Results BAIBA treatment ameliorated impairment of insulin receptor substrate (IRS)-1/Akt-mediated insulin signalling in palmitate-treated C2C12 myocytes and in skeletal muscle of HFD-fed mice. In addition, BAIBA treatment reversed HFDinduced increases in body weight and improved impaired glucose tolerance in mice. In vitro and in vivo, inhibitory κBα (IκBα) phosphorylation, nuclear factor κB (NFκB) nuclear translocation and downstream inflammatory cytokines were significantly suppressed by BAIBA. Furthermore, BAIBA treatment significantly induced AMPK phosphorylation and expression of PPARδ in C2C12 myocytes and in skeletal muscle of mice. Both compound C, an AMPK inhibitor, and Pparδ (also known as Ppard) siRNA abrogated the inhibitory effects of BAIBA on palmitate-induced inflammation and insulin resistance. BAIBA significantly induced the expression of genes associated with fatty acid oxidation, such as carnitine palmitoyltransferase 1 (Cpt1), acyl-CoA oxidase (Aco; also known as Acox1) and fatty acid binding protein 3 (Fabp3); this effect of BAIBA was significantly reduced by compound C and Pparδ siRNA. Conclusions/interpretation These results are the first to demonstrate that BAIBA attenuates insulin resistance, suppresses inflammation and induces fatty acid oxidation via the AMPK-PPARδ pathway in skeletal muscle.
Introduction
Although regular exercise increases insulin sensitivity in humans [1] , the underlying mechanisms are not completely understood. Begriche et al demonstrated that β-aminoisobutyric acid (BAIBA), a natural catabolite of thymine, reduced body fat percentage through increased fatty acid oxidation and decreased de novo lipogenesis in mice [2] . Recently, Roberts et al identified BAIBA as a small molecule myokine secreted from myocytes with forced expression of peroxisome proliferator-activated receptor-gamma coactivator-1α (PGC-1α). BAIBA enhances the browning of white adipose tissue and β-oxidation in the liver through a mechanism mediated by peroxisome proliferator-activated receptor α (PPARα) [3] . Elevated plasma NEFA levels are observed in individuals with insulin resistance [4] . In particular, saturated NEFA has been reported to induce insulin resistance [5] . Moreover, elevated levels of saturated NEFA induce inflammation, which results in insulin resistance via several pathways involving diacylglycerol-mediated protein kinase C activation [6] or Toll-like receptors [7] . These pathways lead to activation of nuclear factor-κB (NFκB), a proinflammatory transcription factor, which impairs insulin signalling in skeletal muscle [8] . Under inflammatory conditions, NFκB induces the expression of various proinflammatory cytokines, such as TNF-α and IL-6, which are associated with insulin resistance and type 2 diabetes [9] .
The current study investigated the influence of the novel myokine BAIBA, which exerts ameliorating effects on inflammation and insulin resistance. Furthermore, to elucidate the cellular mechanisms through which BAIBA influences inflammation and insulin resistance, we explored a downstream signal transduction pathway involving AMPactivated protein kinase (AMPK) and PPARδ in C2C12 myocytes and in mouse skeletal muscle.
Methods
Cell cultures, reagents and antibodies The mouse skeletal muscle cell line C2C12 (ATCC, Manassas, VA, USA) was cultured in Dulbecco's modified eagle medium (DMEM) (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (Invitrogen), 100 units ml −1 penicillin and 100 μg ml −1 streptomycin (Invitrogen). Cells were incubated in a humidified atmosphere of 5% CO 2 at 37°C. Cells were supplemented with 2% horse serum to induce differentiation. Immunoblotting analysis C2C12 cells were harvested and proteins were extracted with lysis buffer (PRO-PREP ™ ; Intron Biotechnology, Seoul, Korea) for 60 min at 4°C. Protein samples (30 μg) were subjected to 10% SDS-PAGE, transferred to a nitrocellulose membrane (Amersham Bioscience, Westborough, MA, USA) and probed with primary antibody followed by secondary antibody conjugated with horseradish peroxidase (Amersham Bioscience). The samples were detected with chemiluminescence kits (Amersham Bioscience).
Transfections using siRNAs 0-20 nmol/l small interfering (si)RNA oligonucleotides for PPARδ (SC-36305; Santa Cruz Biotechnology) were used to suppress gene expression. Transfection was performed with Lipofectamine 2000 (Invitrogen), in accordance with the manufacturer's directions.
Measurement of NFκB nuclear translocation Cells were fractionated using a Nuclear/Cytosol Fractionation Kit, as described in the manufacturer's instructions (Biovision, Milpitas, CA, USA).
Glucose uptake, acetyl-CoA and ATP measurement Glucose uptake levels, intracellular acetyl-CoA and ATP in cells or tissues were measured using assay kits, as described in the manufacturer's directions (Abcam, Cambridge, MA, USA).
Statistical analysis All analyses were performed using the SPSS/PC statistical program (version 12.0 for Windows; SPSS, Chicago, IL, USA). Results are presented as the fold difference relative to control values (mean ± SEM). All of the in vitro experiments were conducted a minimum of three times. Student's t test or two-way ANOVA were used in the statistical analysis.
Results
BAIBA treatment prevents hyperlipidaemia-induced insulin resistance in C2C12 myocytes and skeletal muscle of HFD-fed mice To evaluate the effects of BAIBA on palmitate-induced insulin resistance, we examined the effect of BAIBA on the levels of insulin-stimulated Akt and IRS-1 phosphorylation. It has been reported that plasma concentration of BAIBA was 8.9±0.5 μmol/l in mice treated with 170 mg kg −1 day −1 of BAIBA [3] . Therefore, C2C12 mouse skeletal muscle cells were treated with 0-20 μmol/l for 5 days. First, C2C12 mouse skeletal muscle cells treated with palmitate and isolated soleus skeletal muscle from HFD-fed mice showed impaired insulin sensitivity. However, BAIBA treatment significantly reversed these changes both in vitro and in vivo (Fig. 1a-c) .
BAIBA ameliorates HFD-induced insulin resistance in mice We next examined the effect of BAIBA on glucose tolerance and insulin sensitivity by performing an IPGTT and ITT. The IPGTT and ITT revealed that the HFD significantly impaired glucose tolerance and increased insulin resistance compared with the ND. However, BAIBA treatment significantly improved HFD-induced glucose tolerance and insulin resistance (Fig. 2a,b) . As HFD-induced basal serum glucose levels were suppressed by BAIBA administration (ND: 6.43± 0.15 mmol/l; HFD: 9.32±0.44 mmol/l; HFD+BAIBA: 6.74± 0.29 mmol/l), it was difficult to evaluate the ITT results. Therefore, we used a graph in % of basal glycaemia to estimate the effect of BAIBA on insulin sensitivity (Fig. 2b) . Furthermore, BAIBA administration significantly decreased the HFD-induced increase in body weight (Fig. 2c) , in agreement with previous reports [3] . However, BAIBA treatment did not affect food intake represented by energy intake (Fig. 2d) .
BAIBA alleviates palmitate-induced inflammation in C2C12 cells and soleus skeletal muscle of HFD-fed mice BAIBA ameliorated palmitate-induced IκBα phosphorylation, NFκB nuclear translocation, and the expression of IL-6 (a cytokine positively regulated by NFκB) [9, 10] in a dose-dependent manner (Fig. 3a) . Furthermore, BAIBA administration resulted in significant suppression of HFD-induced IκBα phosphorylation and NFκB nuclear translocation in the soleus skeletal muscle of mice (Fig. 3b,c) . Serum TNF-α and monocyte chemotactic factor-1 (MCP-1) levels were also decreased by BAIBA treatment (Fig. 3d,e) .
BAIBA prevents palmitate-induced inflammation, which leads to improvements in insulin resistance through activation of AMPK It has been reported that AMPK is a therapeutic target for treatment of insulin resistance and type 2 diabetes [11] . In the present study, BAIBA induced AMPK phosphorylation in a dose-dependent manner (Fig. 4a) . Since the association of inflammation with insulin resistance has been reported [12] , we next verified the inhibitory effect of BAIBA on palmitateinduced inflammation through the AMPK-dependent pathway. As shown in Fig. 4b , palmitate increased IκBα phosphorylation, NFκB nuclear translocation and IL-6 expression. Notably, the suppressive effects of BAIBA on palmitate-induced inflammation were significantly reversed in the presence of compound C and Ampk siRNA (Fig. 4b,d ). We then evaluated whether BAIBA-induced AMPK contributed to improvements in insulin resistance aggravated by palmitate in C2C12 myocytes. As shown in Fig. 4c and e, treatment of C2C12 cells with BAIBA significantly reversed palmitate-induced insulin resistance, as demonstrated by impairment of insulin-stimulated IRS-1 and Akt phosphorylation. The reversible effects of BAIBA on palmitate-induced inflammation and insulin resistance were significantly abolished by both compound C and siRNA for Ampk (Fig. 4c,e) . Furthermore, BAIBA administration significantly reversed HFD-suppressed AMPK phosphorylation in the soleus skeletal muscle of mice (Fig. 4f) .
The PPARδ-mediated pathway is involved in the inhibitory effects of BAIBA on palmitate-induced inflammation and insulin resistance Narkar et al reported that AMPK activates genes associated with β-oxidation via PPARδ [13] . PPARδ and its ligand are targets for the treatment of inflammation [14] [15] [16] and insulin resistance [17] [18] [19] . Thus, we examined whether BAIBA augmented PPARδ expression in C2C12 cells. Treatment of C2C12 cells with BAIBA induced PPARδ expression in a dosedependent manner (Fig. 5a ). PPARδ expression was effectively suppressed by a Pparδ (also known as Ppard) siRNA. The Pparδ siRNA significantly abrogated the effect of BAIBA on palmitate-induced inflammation and insulin resistance (Fig. 5b,c) , suggesting that BAIBA attenuates palmitate-induced inflammation and insulin resistance via the PPARδ-mediated pathway. In agreement with the in vitro data, BAIBA administration significantly augmented PPARδ expression in soleus skeletal muscle from HFD-fed mice (Fig. 5d) . BAIBA independently increased PPARδ expression and AMPK phosphorylation (Fig. 5e,f) .
BAIBA induces fatty acid oxidation through AMPKmediated pathways in C2C12 myocytes and in skeletal muscle of HFD-fed mice It has been reported that incomplete fatty acid oxidation contributes to skeletal muscle insulin resistance [20] . As AMPK and PPARδ, as well as BAIBA, have been reported to induce fatty acid oxidation [3, 21, 22] , we evaluated whether BAIBA-induced AMPK and PPARδ could induce fatty acid oxidation in C2C12 myocytes. As shown in Fig. 6a and b, inhibition of AMPK by compound C and suppression of PPARδ by siRNA significantly abrogated the inducible effect of BAIBA on genes associated with fatty acid oxidation, such as Cpt1, Aco (also known as Acox1) and Fabp3 ) for 8 weeks. Serum analysis of (d) TNFα and (e) MCP-1 of mice treated with HFD and BAIBA (seven animals per treatment group). Mean ± SEM were calculated from the data obtained from seven separate animals. ***p<0.001, **p<0.01 and *p<0.05 when compared with the control or the ND treatment. † † p<0.01 and † p<0.05 when compared with the palmitate or the HFD treatment. In (b), as the sample was misloaded, the HFD group in the third position was moved to the second position (Fig. 6a,b) . Furthermore, BAIBA administration significantly increased the mRNA expression levels of Cpt1, Aco and Fabp3 in the soleus skeletal muscle of mice (Fig. 6c) .
Acetyl-CoA and ATP, products of fatty acid oxidation, were also measured. BAIBA administration significantly increased both intracellular acetyl-CoA and ATP (Fig. 6d) . 
Discussion
Exercise is known to be an effective intervention for the treatment of insulin resistance and type 2 diabetes [1] . During exercise, secretion of BAIBA from skeletal muscle to the blood is enhanced through activation of PGC1α [3] . BAIBA can convert white adipose tissue to brown adipose tissue, which plays beneficial roles in the regulation of glucose metabolism and insulin sensitivity [3, 23] . Moreover, plasma BAIBA levels are inversely associated with metabolic risk variables and are increased with exercise [3] . Therefore, Roberts et al suggested that BAIBA may contribute to exerciseinduced protection from metabolic disease [3] . However, the mechanisms by which BAIBA may improve insulin resistance in skeletal muscle remain unknown.
AMPK is the master regulator of energy homeostasis and has been reported to inhibit inflammation through inhibition of NFκB signalling [24] . AMPK plays a pivotal role in metabolic diseases such as obesity and type 2 diabetes. Obesityinduced increases in serum NEFA concentration can suppress AMPK activity [25] and impair insulin signalling [26] . High blood glucose levels in patients with type 2 diabetes also induce oxidative stress and activate NFκB. Conversely, AMPK activation can suppress reactive oxygen species production [27] and can augment the expression of thioredoxin, an inhibitor of the inflammatory response [28, 29] . Increased AMPK activity also attenuates endoplasmic reticulum stress, which results in inhibition of inflammation [30, 31] . AMPK is activated in the muscle of patients with type 2 diabetes during exercise [32] . The present study showed that BAIBA significantly induces AMPK phosphorylation. Furthermore, suppression of AMPK abrogated the suppressive effects of BAIBA on inflammation and insulin resistance. These results reveal one possible mechanism through which the beneficial effects of exercise may be mediated through BAIBA.
PPARδ has emerged as an important metabolic regulator that may mediate the favourable effects of exercise in diverse tissues, such as fat, skeletal muscle, liver and heart. PPARδ receptor activation by a ligand mitigates the macrophagemediated inflammatory response and regulates lipoprotein metabolism to decrease triacylglycerol and increase HDLcholesterol levels. Furthermore, PPARδ activation in the liver suppresses hepatic glucose output, leading to attenuation of hyperglycaemia and amelioration of lipopolysaccharideinduced inflammation through inhibition of NFκB activity and TNF-α expression in cardiomyocytes [14] . Fatty acid oxidation and energy dissipation in skeletal muscle and adipose tissue by PPARδ activation exerts many beneficial effects, including reducing body weight, increasing skeletal muscle metabolic rate and exercise endurance, improving insulin sensitivity and lipid profiles and suppressing atherogenic inflammation [33] . Therefore, PPARδ is an exciting new target for the treatment of the metabolic syndrome [33] . The present study is the first to show that BAIBA treatment can increase the expression of PPARδ, resulting in alleviation of inflammation through suppression of the NFκB pathway and reduction of proinflammatory cytokines.
By administration of BAIBA to palmitate-treated myocytes, we demonstrated that BAIBA-induced activation of AMPK and PPARδ was responsible for a reduction in inflammation. Previous studies have shown that NEFAs can induce inflammation via NFκB activation and upregulation of additional mediators, such as TNF-α and IL-6 [34, 35] . Consistent with previous reports, the present study confirmed that palmitate increased IκBα phosphorylation, NFκB nuclear translocation and IL-6 expression, which together result in impaired insulin-stimulated IRS-1 and Akt phosphorylation in C2C12 myocytes. Furthermore, suppression of both AMPK and PPARδ significantly abrogated the suppressive effects of BAIBA on palmitate-induced inflammation, suggesting that induction of AMPK and PPARδ by BAIBA contributes to the attenuation of palmitate-induced inflammation. In agreement with the changes in inflammation markers, BAIBA attenuated palmitate-induced elevation of insulin-stimulated IRS-1 and Akt phosphorylation. In vivo experiments using HFD-fed mice also yielded similar results in that BAIBA inhibited the NFκB pathway and the downstream proinflammatory cytokines, such as TNF-α and MCP-1. Overall, these findings suggest that BAIBA alleviates insulin resistance induced by palmitate or an HFD through attenuation of inflammation via an AMPK-PPARδ-dependent pathway in skeletal muscle. Furthermore, BAIBA improved glucose tolerance and insulin tolerance in mice. In this study, elevated basal glucose levels were detected in experimental mice by performing IPGTTs and ITTs after hyperglycaemia developed as a result of an HFD. Owing to a difference in basal plasma glucose levels, a graph of percentage of basal glycaemia was used to estimate insulin sensitivity in the present study. Furthermore, our study showed that HFD-induced basal plasma glucose levels were suppressed by BAIBA administration. This suppressive effect of BAIBA on basal serum glucose levels may be associated with hepatic gluconeogenesis regulated by PPARδ [17] or other pathways.
Interestingly, BAIBA administration decreased the body weight of experimental mice, although it did not affect energy intake. These results suggest that loss of body weight is not due to a change in energy intake, but internal mechanisms including fat burning by fatty acid oxidation. Begriche et al indicated no change in body weight but decrease in fat mass by BAIBA treatment in ob/ob mice [2] . This discrepancy may be due to differences in study protocol and experimental animal models.
In agreement with the findings reported by Roberts et al demonstrating that BAIBA induces hepatic fatty acid oxidation through a PPARα-dependent pathway [3] , we also confirmed the role of BAIBA-induced β-oxidation in mouse skeletal muscle cells. Interestingly, the expression levels of PPARδ and β-oxidationassociated genes were increased in the skeletal muscle of HFD-fed mice in the present study. Although the reason for this result is not clear, differences in the stimuli might be involved. This increase in PPARδ expression might be mediated by other HFD-induced molecules. Furthermore, the induction of PPARδ by the HFD may play a role in the compensatory effects needed to maintain lipid homeostasis. The mechanism of PPARδ regulation by an HFD will need to be elucidated in future studies. However, in agreement with our current in vitro experiments, BAIBA administration actively upregulated AMPK phosphorylation and PPARδ expression levels in skeletal muscle of HFD-fed mice.
In summary, the present study is the first to demonstrate that BAIBA attenuates insulin resistance and inflammation induced by palmitate or an HFD through a pathway mediated by AMPK-PPARδ in skeletal muscle. These results may provide insight into the novel mechanisms contributing to the beneficial effects of exercise and may suggest a therapeutic approach to insulin resistance and type 2 diabetes. Duality of interest The authors declare that there is no duality of interest associated with this manuscript.
